Eli Lilly

KISUNLA

ASP | WAC | AWP at the HCPCS Unit

Manufacturer:

Eli Lilly

Kisunla HCPCS:

J0175

HCPCS Code Descriptor:

Injection, donanemab-azbt, 2 mg

Category:

J Code

Kisunla NDCs:

00002-9401-01

Primary Type:

Neurology

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intravenous

KISUNLA CPT Codes:

96413: Chemotherapyadministration, IV infusiontechnique; up to 1 hour, single orinitial substance/drug

96365: IV infusion, for therapy,prophylaxis, or diagnosis (specifysubstance or drug); initial, up to1 hour

Some of the most common CPT administration codes for 'buy and bill' drugs can be found at the following link:

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Kisunla:

Kisunla is a neurology drug manufactured by Eli Lilly and administered via the intravenous route of administration. The J Code: J0175 is aligned to the drug SPINRAZA.

ACCESS PRICING AND MORE BY REGISTERING

J0175 Added Date:

July 2, 2024

J0175 Effective Date:

July 2, 2024

J0175 Termination Date:

HCPCS Active

Kisunla billing and coding information can be found through Eli Lilly at the link below:
Kisunla patient assistance information can be found through Eli Lilly.
Kisunla prescribing information can be found at the link below:
Information regarding Kisunla’s side effects can be found through the FDA.